1. Sharp AL, et al. Journal of general internal medicine, 37(4), 745–752. https://doi.org/10.1007/s11606-021-06841-2
2. Hutchinson et al. BMC Pulmonary Medicine. (2017) 17:53, DOI 10.1186/s12890-017-0396-4.
3. https://www.goodrx.com/healthcare-access/patient-advocacy/avoid-er-for-non-emergencies
Our portable home reader NanoPAL™ together with our ultra-sensitive SeraParma™ tests helps telehealth physicians assess multiple biomarker testing results, enabling an astute determination for the crucial next steps for a patient while at home.
There is strong evidence of the benefits of primary care for both populations and personal health. With only 15 minutes of turnaround time, our solution will accelerate physicians’ decision-making in outpatient settings and reduce 80-90% of the unnecessary hospital ER visits and related expenditures.
Our portable home reader NanoPAL™ together with our ultra-sensitive SeraParma™ tests helps telehealth physicians assess multiple biomarker testing results, enabling an astute determination for the crucial next steps for a patient while at home.
There is strong evidence of the benefits of primary care for both populations and personal health. With only 15 minutes of turnaround time, our solution will accelerate physicians’ decision-making in outpatient settings and reduce 80-90% of the unnecessary hospital ER visits and related expenditures.
In addition to our handy home tests and readers, we also will provide a comprehensive online disease and lifestyle management platform for patients.
This service will help patients better understand their prognosis of disease and then prevent their conditions from worsening.
Patients’ life quality can be improved by reducing hospitalization frequency and unnecessary concerns about false alarms.
Ambulatory care and telehealth providers are equipped to resolve most health issues in non-hospital settings.
The healthier the insured is, the more profitable the insurer is; payers will be more willing to reimburse home tests and disease management solutions.
CEO
CSO
CSO
CTO
CTO
@ 2022 NanoParma Biomedical, LLC.
@ 2022 NanoParma Biomedical, LLC.